In short
Clinical trials are studying Linezolid in many different infections and patient groups. These studies look at how well it works, how safe it is in trial settings, and what outcomes matter most, such as cure, relapse, survival, or hospital readmission. The trials include adults, children, and critically ill patients.
Key points
- Clinical trials investigating Linezolid are testing it in many infection settings, including diabetic foot infections, bloodstream infections, bone and joint infections, sepsis, tuberculosis, syphilis, and brain abscess. Most studies are Phase 3 trials, with some Phase 2 and Phase 1 studies, so the research includes both larger confirmatory trials and earlier studies. The target populations include adults, children, and critically ill patients. The main outcomes often focus on clinical response, cure, relapse, survival, readmission, and safety. Some studies also measure drug levels in the body or compare Linezolid with other treatment strategies.
Clinical trials overview
Several studies in the source data include Linezolid as one of the study treatments. These trials do not all test the same question: some compare Linezolid with another antibiotic, some look at treatment length, and some study whether it can help prevent infection-related problems after surgery or other procedures.
The research settings are very different. Linezolid is being studied in infections such as diabetic foot infections, sepsis, bloodstream infections, bone and joint infections, tuberculosis, syphilis, brain abscess, and other serious bacterial infections.
Patient groups and conditions studied
Many trials focus on adults with serious infections. Examples include adults with Staphylococcus aureus bacteremia, enterococcal bacteremia, sepsis, pyogenic vertebral osteomyelitis, periprosthetic joint infection, and pyogenic liver abscess.
Some studies look at people with infections linked to surgery or implanted material, such as surgical site infection prophylaxis after surgery, infection after cystectomy, and infections of hip or knee prostheses.
Other studies focus on special infection groups, including people with pulmonary tuberculosis, Mycobacterium abscessus lung disease, syphilis, brain abscess, and critically ill patients in the intensive care unit (ICU).
Children are also included in some trials. One study looks at pediatric participants with serious gram-negative infections, and another studies antibiotic levels in cerebrospinal fluid, which is the fluid around the brain and spinal cord, in children with external ventricular drain or malignant brain tumors.
Trial designs and phases
Most Linezolid trials in the source data are Phase 3 studies. Phase 3 usually means a larger trial that compares treatments in many patients to confirm benefit and safety in a real clinical setting.
There are also earlier studies. Some are Phase 2 studies, which often look more closely at whether a treatment works and whether it is tolerated, and one study is Phase 1, which is usually an early study of how a treatment behaves in the body.
Several trials are randomized, meaning participants are assigned by chance to one treatment group or another. Some are non-inferiority trials, which ask whether a shorter, simpler, or new treatment is not worse than the standard treatment by more than a small preset amount.
Main outcomes measured
The main outcome in many studies is some form of clinical success, which means the patient improves and does not show signs that the infection has returned or worsened.
Some trials measure survival, such as all-cause mortality at 90 days or 30 days. Others measure relapse, recurrence, microbiological failure, or the need for extra antibiotic treatment or surgery.
Safety outcomes are also important. One sepsis trial using personalized Linezolid dosing measures thrombocytopenia, which means a drop in platelet count, and another trial in diabetic foot infections compares both clinical response and safety/tolerability against Linezolid.
Some studies focus on drug exposure in the body rather than direct infection outcomes. For example, the ICU pharmacokinetic study measures antibiotic plasma targets, and pediatric studies measure concentrations in cerebrospinal fluid.
Special populations and monitoring studies
In critically ill patients, Linezolid is part of studies that examine antibiotic monitoring and dosing strategy. These studies try to understand whether measuring drug levels or using personalized dosing can improve treatment results or reduce problems such as low platelets.
In children, Linezolid appears in studies that look at how antibiotics move into cerebrospinal fluid. This is important because the researchers want to know whether the drug reaches the area around the brain at useful levels.
Some trials also include Linezolid as one option among several antibiotics in broad infection studies. These are not always trials of Linezolid alone, but Linezolid is part of the treatment choices being compared.
Selected Linezolid trials
The following trials show the range of questions being studied with Linezolid:
- NCT05369052 studies adults with moderate or severe diabetic foot infections and compares contezolid acefosamil/contezolid with Linezolid. The main outcomes are clinical response at day 35 and safety/tolerability.
- NCT05137119 studies Staphylococcus aureus bacteremia and looks at all-cause mortality at 90 days across a platform of treatment options that includes Linezolid.
- 2024-513890-30-00 studies sepsis and compares personalized Linezolid dosing with standard dosing. The main outcome is thrombocytopenia.
- NCT04140903 studies bacterial brain abscess and compares oral antibiotics, including oral Linezolid, with intravenous treatment. The main outcome is a 6-month composite measure of death, rupture, aspiration, relapse, or recurrence.
- 2023-507617-96-01 studies pyogenic vertebral osteomyelitis and asks whether early switch to oral treatment, including Linezolid, is non-inferior to longer intravenous treatment.
- NCT05069974 studies early syphilis and compares oral Linezolid with standard benzathine benzylpenicillin for clinical, serological, and molecular cure.
- NCT05534750 studies early suspected pulmonary tuberculosis and measures early bactericidal activity, which means how quickly the treatment lowers the number of bacteria in sputum.
- NCT04310930 studies Mycobacterium abscessus lung disease and measures microbiological clearance and tolerance, with Linezolid included among multiple possible treatment regimens.
- 2023-504480-17-00 studies critically ill ICU patients and measures ICU stay, hospital stay, ventilation days, biomarkers, organ failure scores, and 30-day mortality while including Linezolid among the antibiotics under review.
- 2024-515791-12-00 and 2024-518808-43-00 are pediatric pharmacokinetic studies that measure Linezolid concentrations in cerebrospinal fluid and plasma.